About Delve Bio
Delve Bio is a biotechnology company that uses metagenomic next-generation sequencing (mNGS) to empower labs and clinicians to diagnose routine and rare infectious diseases with a single, pathogen-agnostic test. Its flagship product, Delve Detect, identifies bacteria, viruses, fungi, and parasites from cerebrospinal fluid samples, targeting central nervous system infections. The company serves hospitals and laboratories seeking faster, more accurate infectious disease diagnostics.
Company details
Funding
Total raised
$35M
Last stage
Series A
Investors
Founders
Joe DeRisi
World-renowned genomics researcher and professor at UCSF; co-founder of the Chan Zuckerberg Biohub.
Charles Chiu
Co-founder of Delve Bio and professor at UCSF. World leader in genomics and metagenomics for infectious disease. Author of 200+ peer-reviewed publications, holds 15+ patents. Also serves on the scientific advisory boards of Mammoth Biosciences and others.
Matthew Meyerson
Co-founder of Delve Bio. World leader in genomics affiliated with Harvard Medical School and the Broad Institute of MIT and Harvard.
Bradley Murray
Co-founder and CEO of Delve Bio. Previously a senior associate at Xontogeny making seed and Series A investments in life sciences. Earlier was a computational biologist at Intellia Therapeutics and a computational associate at The Broad Institute. Holds a BS from Georgetown University and an MBA from Boston College.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.